Synergy Pharmaceuticals Inc. (Nasdaq: SGYP) to Ring The Nasdaq Stock Market Closing Bell
December 09 2016 - 10:00AM
What: Synergy Pharmaceuticals Inc.
(Nasdaq:SGYP), a biopharmaceutical company focused on the
development and commercialization of novel gastrointestinal (GI)
therapies, will visit the Nasdaq MarketSite in Times Square, in
celebration of its 5 year listing anniversary.
In honor of the occasion, Gary S. Jacob, Ph.D., Chairman
of the Board and CEO, will ring the Closing
Bell.
Where:Nasdaq MarketSite – 4 Times Square – 43rd
& Broadway – Broadcast Studio
When:Monday, December 12, 2016 – 3:45 p.m. to
4:00 p.m. ET
Synergy Media Contact:Gem
Hopkins212-297-0020ghopkins@synergypharma.com
Nasdaq MarketSite:Emily Pan(646)
441-5120emily.pan@nasdaq.com
Feed Information:Fiber Line (Encompass
Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC
3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
Social Media:For multimedia features such as
exclusive content, photo postings, status updates and video of bell
ceremonies, please visit our Facebook
page:http://www.facebook.com/NASDAQ.
For photos from ceremonies and events, please visit our
Instagram page:http://instagram.com/nasdaq
For livestream of ceremonies and events, please visit our
YouTube page:http://www.youtube.com/nasdaq/live
For news tweets, please visit our Twitter
page:http://twitter.com/nasdaq
For exciting viral content and ceremony photos, please visit our
Tumblr page:http://nasdaq.tumblr.com/
Webcast:A live stream of the Nasdaq Closing
Bell will be available
at: https://new.livestream.com/nasdaq/live or
http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos: To obtain a hi-resolution
photograph of the Market Close, please go to
http://business.nasdaq.com/discover/market-bell-ceremonies and
click on the market close of your
choice.
About Synergy Pharmaceuticals Inc.Synergy is a
biopharmaceutical company focused on the development and
commercialization of novel gastrointestinal (GI) therapies. The
company has pioneered discovery, research and development efforts
around analogs of uroguanylin, a naturally occurring human GI
peptide, for the treatment of GI diseases and disorders. Synergy
discovered, is developing and controls 100% worldwide rights to its
proprietary uroguanylin analog platform that includes two lead
product candidates – plecanatide and dolcanatide. Plecanatide is
Synergy’s first uroguanylin analog currently being evaluated for
use as a once-daily tablet for chronic idiopathic constipation and
irritable bowel syndrome with constipation. Dolcanatide is
Synergy’s second uroguanylin analog currently being explored for
ulcerative colitis. For more information, please
visit www.synergypharma.com.
About NasdaqNasdaq (Nasdaq:NDAQ) is a leading
provider of trading, clearing, exchange technology, listing,
information and public company services across six continents.
Through its diverse portfolio of solutions, Nasdaq enables
customers to plan, optimize and execute their business vision with
confidence, using proven technologies that provide transparency and
insight for navigating today's global capital markets. As the
creator of the world's first electronic stock market, its
technology powers more than 70 marketplaces in 50 countries, and 1
in 10 of the world's securities transactions. Nasdaq is home to
more than 3,700 listed companies with a market value of $10.0
trillion and approximately 18,000 corporate clients. To learn more,
visit: nasdaq.com/ambition or business.nasdaq.com
-NDAQA-
Nasdaq (NASDAQ:NDAQ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nasdaq (NASDAQ:NDAQ)
Historical Stock Chart
From Apr 2023 to Apr 2024